Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.75 |
| ▸ | HPGD | P15428 | 3/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | HTT | P42858 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9133608 | 0.90 | MAPT (0.83) | MAPTKMT2AHPGDSMN1; SMN2MEN1 | |
| SCHEMBL6257175 | 0.85 | KMT2A (0.69) | MAPTKMT2AHPGDSMN1; SMN2LMNA | |
| SCHEMBL6259345 | 0.83 | KDR (0.61) | MAPTKMT2AHPGDSMN1; SMN2LMNA | |
| SCHEMBL2885143 | 0.81 | HPGD (0.61) | MAPTKMT2AHPGDSMN1; SMN2LMNA | |
| SCHEMBL8117886 | 0.80 | KDM4E (1.00) | MAPTHPGDHTTALDH1A1TP53 | |
| SCHEMBL6857725 | 0.78 | HPGD (0.62) | MAPTKMT2AHPGDSMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL31682859 | 0.77 | KDM4E (0.73) | MAPTHPGDHTTALDH1A1TP53 | |
| SCHEMBL28111801 | 0.76 | KDM4E (0.74) | MAPTHPGDHTTALDH1A1TP53 | |
| SCHEMBL6859385 | 0.76 | HTR6 (0.61) | MAPTKMT2AHPGDSMN1; SMN2LMNA | |
| SCHEMBL5813055 | 0.75 | TUBB4A (0.80) | MAPTKMT2AHPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0999834-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-10-12 | — | — | EP | disclosed |
| US-6586459-B2 | Inhibitors of factor Xa; for example 3-(4-tert-butylbenzoyl)amino-N-(4-methoxyphenyl)-2-thiophenecarboxamide | BEIGHT DOUGLAS WADE (US) | 2003-07-01 | — | — | US | disclosed |
| US-6583173-B2 | Useful as anticoagulants in mammals; inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-06-24 | — | — | US | disclosed |
| US-20020072531-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-06-13 | — | — | US | disclosed |
| US-20020049234-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-04-25 | — | — | US | disclosed |
| US-6313151-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072531-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | MAPT 4730/4885KMT2A 4505/4885HPGD 225/4885 |
| US-20020049234-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | MAPT 4730/4885KMT2A 4505/4885HPGD 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.